Ensysce Biosciences, Inc. (ENSC)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Ensysce Biosciences, Inc. reported revenue of $5.07M, down 2.8% from the prior year. The company ran a net loss, with a net margin of -200.8%. It held $7.45M in total assets against $4.57M in total liabilities.
Key ratios (FY2025)
-202.1%
Operating margin
-200.8%
Net margin
-316.6%
Return on equity
-2.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M | $3.93M | — | — | — |
| Operating Income | -$10.24M | -$6.73M | -$10.72M | -$24.22M | -$19.87M | -$1.61M | -$3.33M | -$959.2K | — |
| Net Income | -$10.18M | -$7.99M | -$10.63M | -$24.21M | -$29.15M | -$160.9K | -$1.07M | $2.05M | — |
| EPS (Diluted) | $-3.98 | $-11.45 | $-70.40 | $-139.42 | $-1.48 | $0.00 | — | — | — |
| Total Assets | $7.45M | $5.60M | $2.71M | $5.89M | $16.42M | $351.8K | $196.51M | $204.83M | $202.43M |
| Total Liabilities | $4.57M | $2.22M | $3.36M | $9.91M | $24.58M | $7.01M | $17.50M | $13.17M | $12.82M |
| Shareholders' Equity | $3.21M | $3.71M | -$322.9K | -$3.71M | -$7.88M | -$6.44M | $5.00M | $5.00M | $5.00M |
| Cash & Equivalents | $4.31M | $3.50M | $1.12M | $3.15M | $12.26M | $194.2K | — | — | — |
| Operating Cash Flow | -$7.81M | -$7.50M | -$10.78M | -$17.89M | -$8.24M | -$1.25M | -$1.42M | -$1.24M | — |
| Capital Expenditures | $123.6K | — | — | — | — | — | — | — | — |
| Shares Outstanding | 4.57M | 1.36M | 209.7K | 534.5K | 1.23M | 15.77M | 7.07M | 6.04M | 6.73M |